3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Conditions
Glioma
3
Glioblastoma
3
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Gliosarcoma
2
Brain Neoplasms
2
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Disease
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Interventions
Vincristine
2
Oncolytic Virotherapy
2
pralsetinib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
cixutumumab
1
Valproic Acid
1
Radiotherapy
1
Radiation
1
Maintenance Chemotherapy
1
Lomustine
1
Interferon-gamma
1
Immunotherapy
1
Etoposide
1
Doxorubicin
1
Cyclophosphamide
1
Cisplatin
1
Antibodies, Monoclonal
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Neuroectodermal Tumors
×
Oncolytic Virotherapy
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled